Lead Sponsor

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Age

30 - 75 years

Sex

ALL

Healthy Volunteers

Yes

•Age 30-75 years
•Known Diabetes Mellitus (HgA1c \>6.5%, fasting blood sugar \>125 mg/dl, taking anti- diabetes medications)
•Subjects must provide written informed consent after the scope and nature of the investigation has been explained to them
•Calcium Score \>20 at baseline

•A contraindication to AGE including: known hypersensitivity to drug.
•Any unstable medical, psychiatric or substance abuse disorder that in the opinion of the investigator or principal investigator is likely to affect the subject's ability to complete the study or precludes the subject's participation in the study
•Weight in excess of 350 pounds
•Bleeding disorder
•History of known coronary artery disease, myocardial infarction, stroke or life- threatening arrhythmia within the prior six months
•NYHA Class II- IV heart failure
•History of malignancy within the last 5 years (other than skin cancer) or evidence of active cancer which would require concomitant cancer chemotherapy
•Serum creatinine \> 1.4 mg/dl
•Triglycerides \> 400 at visit 1
•Drug or alcohol abuse, or current intake of more than 14 standard drinks per week
•Concurrent enrollment in another placebo-controlled trial
•Partial ileal bypass or known gastrointestinal disease limiting drug absorption
•Current tobacco use
•Current use of anticoagulants (except for anti-platelet agents)
•Renal failure
•History of hypertensive encephalopathy or cerebrovascular accident
•Hematological or biochemical values at screening outside the reference ranges considered as clinically significant in the opinion of the investigator or PI
•Pregnancy